Eculizumab administration for myasthenia gravis also stabilizes thrombogenicity of catastrophic antiphospholipid syndrome
ConclusionsEculizumab can be effective for controlling multiple complement-mediated pathophysiology. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - April 23, 2024 Category: Neurology Authors: Sunao Takahashi,
Nobuo Sanjo,
Ryuji Koike,
Takanori Yokota Tags: CASE REPORT Source Type: research
Clinical Profile, Treatment and Outcome of Thrombotic Thrombocytopenia Purpura (TTP) in Rituximab Era- an Experience from Tertiary Care Centre from North India
AbstractThrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia (MAHA) resulting from severe deficiency of ADAMTS13. TTP is an acute medical emergency which requires early treatment with therapeutic plasma exchange. With the early use of Rituximab along with PLEX, early response is achieved and relapse rate has gone down. There is lack of published data from India regarding treatment and outcome of TTP. We retrospectively analyzed our data of 21 patients of TTP including 4 patients who had TA-TMA. TTP patients were treated with TPE, pulse methylprednisolone and rituximab. After a median follow up o...
Source: Indian Journal of Hematology and Blood Transfusion - April 20, 2024 Category: Hematology Source Type: research
Use of a donor kidney with known autosomal dominant polycystic kidney disease in a highly sensitised paediatric recipient
We report the use of an autosomal-dominant polycystic kidney disease (ADPKD) donor kidney in a paediatric recipient. A 14-year-old boy on haemodialysis for 4 years following loss of a first kidney transplant, highly sensitised, and with limited vascular options for ongoing dialysis access, was offered a deceased brain death donor transplant from a mid-30s donor with known ADPKD but normal kidney function and negligible proteinuria. After extensive discussion with the patient and family, discussing all alternative options and review of available literature, the kidney was accepted and implanted. Graft function was immediate...
Source: Pediatric Nephrology - April 19, 2024 Category: Urology & Nephrology Source Type: research
Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome
ConclusionsLong-term discontinuation of immunosuppressants can be feasible in patients without a relapse on initial immunosuppressants, those with longer relapse-free interval before discontinuation of immunosuppressants, and those without a relapse for one year after discontinuation of immunosuppressants.Trial registrationNot applicable.Graphical abstractA higher resolution version of the Graphical abstract is available asSupplementary information (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - April 19, 2024 Category: Urology & Nephrology Source Type: research
Efficacy and Safety of Weekly Bortezomib-dexamethasone as the Third-Line Therapy for Warm Autoimmune Hemolytic Anemia: a Case Series of 5 Patients
AbstractBackgroundWarm autoimmune hemolytic anaemia (wAIHA) is a chronic condition. Despite the high initial responses seen with the first two treatment lines (corticosteroids and rituximab), relapses are frequent. Anecdotal data suggests the efficacy of bortezomib in relapsed/refractory (RR) wAIHA. This case series aimed to evaluate bortezomib as a third-line therapy in wAIHA in terms of efficacy, safety, and prospects of achieving treatment-free remission (TFR). Five adult patients ≥ 18 years of age with RR wAIHA after corticosteroids and rituximab were included over 1.5 years. Patients were treated uniformly wi...
Source: Indian Journal of Hematology and Blood Transfusion - April 19, 2024 Category: Hematology Source Type: research
B-cell lymphoma with intracellular crystals: a mimic of crystal-storing histiocytosis
A 74-year-old man with chronic kidney disease and splenic marginal zone lymphoma, diagnosed 3 years ago, status post bendamustine and rituximab and now on zanubrutinib due to recurrence, presented with acute kidney injury and proteinuria. On admission, he had a serum creatinine level of 2.7 mg/dl (baseline, ≈1.9 mg/dl), a urine protein-to-creatinine ratio of 5 g/g, and a serum albumin level of 3.2 g/dl. Serum protein electrophoresis showed IgGκ M protein. Serum free light chain ratio was 3.2. (Source: Kidney International)
Source: Kidney International - April 18, 2024 Category: Urology & Nephrology Authors: Michael G. Daniel, Craig R. Soderquist, Satoru Kudose Tags: Nephrology Image Source Type: research
A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England
CONCLUSION: A majority of MG patients required hospitalization or accident and emergency attendance, resulting in high HCRU and costs. A subset of patients required rescue therapy (including IVIg and PLEX), rituximab administration, ventilation, or thymectomy.PMID:38634003 | PMC:PMC11022674 | DOI:10.1177/17562864241237495 (Source: Adv Data)
Source: Adv Data - April 18, 2024 Category: Epidemiology Authors: Jordy van Enkhuizen Jean Binns April Betts Fatemeh Saberi Hosnijeh Myriam Alexander Mark McCormack Saiju Jacob Source Type: research
Safety of Obinutuzumab in children with autoimmune encephalitis and early B cell repopulation on rituximab.
The study objective was to report the use and safety of obinutuzumab in rituximab-resistant children with neurological inflammatory diseases. (Source: Pediatric Neurology)
Source: Pediatric Neurology - April 18, 2024 Category: Neurology Authors: A.T. Nguyen, C. Cotteret, C. Gins, E. Sarda, C. Durrleman, B. Mesples, J. Bustamante, C. Fayard, S. Cisternino, I. Desguerre, M. Aubart Tags: Research Paper Source Type: research
Outcomes of the transformation of follicular lymphoma to diffuse large B ‐cell lymphoma in the rituximab era: A population‐based study
ConclusionThe outcome of t-DLBCL in the rituximab era was better than historical series before the rituximab era. Due to the good prognosis, we did not recommend autologous stem cell transplantation for t-DLBCL receiving watch-and-wait or radiation as initial therapy before HT. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Wenshuai Zheng,
Mingjuan Liu,
Lixun Guan,
Shenyu Wang Tags: RESEARCH ARTICLE Source Type: research
Population pharmacokinetics and exposure –response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
AbstractPolatuzumab vedotin is a CD79b-directed antibody –drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) as first-line treatment of diffuse la rge B-cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful rela...
Source: CPT: Pharmacometrics and Systems Pharmacology - April 16, 2024 Category: Drugs & Pharmacology Authors: Rong Deng,
Leonid Gibiansky,
Tong Lu,
Christopher R. Flowers,
Laurie H. Sehn,
Qi Liu,
Priya Agarwal,
Michael Z. Liao,
Randall Dere,
Calvin Lee,
Gabriel Man,
Jamie Hirata,
Chunze Li,
Dale Miles Tags: ARTICLE Source Type: research
Pulmonology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0613. Online ahead of print.ABSTRACTThe field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifen...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Aram Karkar Sana Khan Rebecca O'Leary Albina Tyker Michael Unger Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
Pulmonology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0613. Online ahead of print.ABSTRACTThe field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifen...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Aram Karkar Sana Khan Rebecca O'Leary Albina Tyker Michael Unger Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
